Analysts Set Disc Medicine, Inc. (NASDAQ:IRON) PT at $85.80

Shares of Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) have been assigned a consensus rating of "Buy" from the ten analysts that are currently covering the company, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $85.80.

A number of analysts have issued reports on the stock. Scotiabank lifted their target price on shares of Disc Medicine from $62.00 to $70.00 and gave the company a "sector outperform" rating in a research note on Tuesday, November 5th. HC Wainwright increased their price target on shares of Disc Medicine from $70.00 to $118.00 and gave the company a "buy" rating in a report on Wednesday. Wedbush restated an "outperform" rating and set a $83.00 price objective (up from $75.00) on shares of Disc Medicine in a research report on Tuesday. Wells Fargo & Company started coverage on Disc Medicine in a report on Thursday, August 22nd. They set an "overweight" rating and a $75.00 price objective on the stock. Finally, Morgan Stanley upgraded shares of Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 target price on the stock in a research note on Tuesday, November 5th.

Disc Medicine Price Performance

NASDAQ IRON traded down $1.21 on Friday, hitting $59.46. 270,748 shares of the company were exchanged, compared to its average volume of 355,189. Disc Medicine has a twelve month low of $25.60 and a twelve month high of $77.60. The company's 50 day moving average price is $51.02 and its 200-day moving average price is $44.75.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping analysts' consensus estimates of ($1.04) by $0.15. On average, analysts predict that Disc Medicine will post -4.15 EPS for the current year.

Insider Buying and Selling at Disc Medicine

In related news, Director William Richard White sold 7,136 shares of the company's stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 7,538 shares of company stock worth $437,875. 4.24% of the stock is currently owned by company insiders.

Institutional Trading of Disc Medicine

Several institutional investors have recently made changes to their positions in the company. Atlas Venture Life Science Advisors LLC raised its stake in shares of Disc Medicine by 9.7% in the second quarter. Atlas Venture Life Science Advisors LLC now owns 2,509,456 shares of the company's stock valued at $113,101,000 after buying an additional 222,223 shares during the period. Wellington Management Group LLP grew its holdings in shares of Disc Medicine by 4.8% during the third quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company's stock worth $90,429,000 after purchasing an additional 83,731 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its position in Disc Medicine by 123.5% during the second quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company's stock valued at $79,090,000 after purchasing an additional 969,834 shares during the last quarter. Deerfield Management Company L.P. Series C raised its position in Disc Medicine by 53.8% during the second quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company's stock valued at $46,119,000 after purchasing an additional 357,730 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Disc Medicine by 59.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company's stock valued at $58,788,000 after purchasing an additional 353,382 shares during the last quarter. Institutional investors own 83.70% of the company's stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.